Marex Group Limited (MRX)
Valuation Overview•Is Marex Group Limited Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
High-quality fundamentals with a strong composite quality score of 75/100, backed by robust profitability and solvency.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Solid fundamental quality, though solvency presents a headwind.
Wall Street is broadly bullish, projecting solid upside. However, capital return yields remain modest, anchored by a strong, well-covered dividend yield.
MRX exhibits elite business quality, driven by exceptional capital efficiency and highly lucrative margins. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company is driving exceptional top-line expansion (41.8% 3Y CAGR) paired with highly explosive earnings growth (41.7% EPS 3Y CAGR). This growth is supported by elite operational efficiency, sustaining an impressive 36.5% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $915.3M | +21.8% | +41.8% | +30.5% | +23.5% | |
| EBITDA | $428.3M | — | +61.5% | — | — | |
| Net Income | $267.7M | +41.4% | +49.8% | — | +33.1% | |
| EPS (Diluted) | $2.96 | +42.3% | +41.7% | +40.0% | +29.6% | |
| Free Cash Flow | $692.0M | -42.8% | +44.7% | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 77.2% | 79.7% | 85.6% | 92.4% |
| Operating Margin | 36.5% | 37.4% | 29.5% | 18.5% |
| Net Margin | 12.5% | 8.9% | 8.6% | 7.0% |
| FCF Margin | 37.2% | 36.6% | 37.8% | 19.0% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q3'26Latest | $1.36 | $1.64 | +20.6% | ||
| Q2'26 | $1.38 | $1.48 | +7.2% | ||
| Q1'26 | $1.02 | $1.13 | +10.8% | ||
| Q4'25 | $0.92 | $0.96 | +4.3% | ||
| Q3'25 | $0.89 | $1.02 | +14.2% | ||
| Q2'25 | $0.89 | $0.91 | +1.9% | ||
| Q1'25 | $0.68 | $0.76 | +11.8% | ||
| Q4'24 | $0.68 | $0.76 | +11.8% |
Total return is +143.0% (1Y), outperforming the benchmark by +128.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +93.0% | +80.3% | — |
| 1Y | +143.0% | +128.0% | +2.1% |
| 3YCAGR | +57.4% | +34.5% | +7.1% |
| 5YCAGR | +31.3% | +18.2% | +7.1% |
| 10YCAGR | +14.6% | +0.7% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Marex Group Limited (MRX) valuation, health, and returns.
Marex Group Limited is estimated to be fair under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. trading near fair value (DCF: $66.59)
Marex Group Limited has multiple valuation anchors: DCF Intrinsic Value: $66.59 | Peer Relative Fair Value: $127.37 | Wall Street Analyst Target: $82.67 (implying +13.6% upside). A convergence of these signals offers higher conviction.
Marex Group Limited displays good financial health with a composite quality score of 75/100, supported by a Piotroski F-Score of 6/9, Return on Invested Capital (ROIC) of 9.4%.
Marex Group Limited pays a 1.0% dividend yield, covered by a 18% payout ratio with 2 years of growth, supplemented by a 0.8% buyback yield.
Marex Group Limited's current growth trajectory is Decelerating. The company achieved +21.8% 1Y revenue growth and +42.3% 1Y EPS growth, compared to its 3Y revenue CAGR of +41.8%.
Wall Street consensus is Buy based on 7 analysts, beating EPS expectations in 100% of recent quarters with a 9-quarter streak. The consensus price target represents a +13.6% change from current levels.
Investment risks for Marex Group Limited include: -20.4% 1-year max drawdown. Volatility risk is characterized by a beta of 0.83x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.